Extending human healthspan by 30+ years

Boris Djordjevic is building an answer to the question that has haunted humanity since consciousness emerged: What if we could add not just years to life, but decades of vigorous health? As founder and architect of the 199 ecosystem, he has constructed something unprecedented—a vertically integrated longevity engine where breakthrough research, clinical translation, diagnostic precision, and industrial-scale manufacturing operate as one synchronized organism.

At the scientific core sits 199 Biotechnologies, where his team has developed a first-in-class cancer therapy using epigenetic reprogramming. The approach is elegantly subversive: instead of destroying cancer cells with toxic compounds, they use transcription factors—engineered OCT4 variants and complementary Yamanaka factors—to rewrite the cancer cell's epigenetic program. Locked in malignant states by epigenetic damage, these cells are coaxed back toward differentiation. Once reprogrammed, they become senescent, then trigger their own programmed death. The lead candidate, E-ON-001, targets glioblastoma—the deadliest brain cancer with a 5% five-year survival rate. In parallel, the team advances senolytic research, developing ultrapotent procyanidin formulations from a library of over 100 screened compounds designed to clear senescent cells safely.

What distinguishes Boris's approach is the refusal to let discovery languish in academic journals. 199 Labs operates GMP-certified facilities in London and Shenzhen, manufacturing over 50 senolytic compounds and 80 senomorphics backed by 8 patents—the world's most comprehensive library of validated longevity therapeutics. This manufacturing capability isn't ancillary; it's the bridge between possibility and reality, turning molecules into medicine at pharmaceutical grade.

The clinical arm closes the loop. 199 Longevity Clinic brings together top integrative medicine specialists who actually collaborate—a rarity in medicine's siloed landscape—to deliver both accessible preventive care and advanced concierge longevity programs. Meanwhile, 199 Diagnostics democratizes measurement through affordable home tests for cellular senescence, NAD+ metabolism, and environmental toxins, giving individuals the data to optimize their biology. Through a joint venture with TripleHelix, he extends this continuum into gene therapy clinical applications. The architecture is deliberate: discover, manufacture, measure, treat, refine—a closed loop of biological intervention operating at the speed of therapeutic urgency.